Guangdong Raynovent Biotechnology Co., Ltd announced that it has received CNY 370 million in a round of funding led by investors Shenzhen Qianhai Xinyi Yide Fund Management Co., Ltd., Efung Capital on January 3, 2023. The transaction also included participation from Guangzhou Guoju Venture Capital Co., Ltd., Wanlian Guangsheng Investment Co., Ltd. and returning investors Guangdong Zhongsheng Pharmaceutical Co., Ltd., Lake Bleu Capital (Hong Kong) Limited.
End-of-day quote
Other stock markets
|
5-day change | 1st Jan Change | ||
14.9 CNY | +2.19% | +3.98% | -7.17% |
Apr. 22 | Guangdong Zhongsheng Pharmaceutical Co., Ltd. Reports Earnings Results for the First Quarter Ended March 31, 2024 | CI |
Mar. 11 | Zhongsheng Pharma's Chairman to Raise Stake in Company | MT |
EPS Revisions
1st Jan change | Capi. | |
---|---|---|
-7.17% | 1.74B | |
+25.83% | 661B | |
+27.00% | 566B | |
-6.76% | 352B | |
+20.34% | 332B | |
+3.00% | 283B | |
+13.09% | 231B | |
+5.46% | 200B | |
-9.61% | 195B | |
-6.26% | 145B |
- Stock Market
- Equities
- 002317 Stock
- News Guangdong Zhongsheng Pharmaceutical Co., Ltd.
- Guangdong Raynovent Biotechnology Co., Ltd announced that it has received CNY 370 million in funding from Shenzhen Qianhai Xinyi Yide Fund Management Co., Ltd., Efung Capital, Guangdong Zhongsheng Pharmaceutical Co., Ltd., Lake Bleu Capital (Hong Kong) Limited, Guangzhou Guoju Venture Capital Co., Ltd., Wanlian Guangsheng Investment Co., Ltd.